Lion Biotechnologies is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate is a ready-to-infuse T-cell therapy utilizing tumor-infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along and a physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, visit the company’s website at www.genesis-biopharma.com.

Let us hear your thoughts below: